SCHEMBL579037

SCHEMBL579037

CCN1CCC(NC)CC1

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.43
KDM4E B2RXH2 4/20 0.42
EPHX1 P07099 2/20 0.41
EPHX2 P34913 1/20 0.41
RECQL P46063 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
MAPT P10636 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.36
CARM1 Q86X55 1/20 0.35
PRMT6 Q96LA8 1/20 0.35
PRMT1 Q99873 1/20 0.35
PRMT8 Q9NR22 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HSD11B1 P28845 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27714482 0.98 SMN1; SMN2 (0.42) SMN1; SMN2KDM4EEPHX1EPHX2RECQL
SCHEMBL5317403 0.91 KDM4E (0.39) SMN1; SMN2KDM4EEPHX1EPHX2RECQL
SCHEMBL26706476 0.88 ACHE (0.41) SMN1; SMN2KDM4EEPHX1EPHX2RECQL
SCHEMBL13832821 0.86
SCHEMBL15079109 0.86
SCHEMBL2549878 0.86
Hydrochloric Acid SCHEMBL13739081 0.84 HRH3 (0.40) SMN1; SMN2KDM4EEPHX1EPHX2RECQL
Hydrochloric Acid SCHEMBL13738417 0.84 HRH3 (0.40) SMN1; SMN2KDM4EEPHX1EPHX2RECQL
Hydrochloric Acid SCHEMBL13738414 0.84 HRH3 (0.40) SMN1; SMN2KDM4EEPHX1EPHX2RECQL
SCHEMBL20960378 0.81 SMN1; SMN2 (0.41) SMN1; SMN2KDM4EEPHX1EPHX2RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119528174-A Modified MWW molecular sieve and preparation method thereof, xylene isomerization catalyst and preparation method and application thereof 中国石油化工股份有限公司 2025-02-28 CN claimed
US-7790885-B2 Process for preparing phenoxypyridine derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-09-07 US claimed
CN-101454286-A Process for producing phenoxypyridine derivative EISAI R&D MAN CO LTD (JP) 2009-06-10 CN claimed
EP-2058302-A1 METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2009-05-13 EP claimed
US-20080214815-A1 Process for preparing phenoxypyridine derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-09-04 US claimed
WO-2007069053-A1 BENZIMIDAZOLE ANTAGONISTS OF THE H-3 RECEPTOR PFIZER PRODUCTS INC. (US) 2007-06-21 WO claimed
CN-119528174-A Modified MWW molecular sieve and preparation method thereof, xylene isomerization catalyst and preparation method and application thereof 中国石油化工股份有限公司 2025-02-28 CN disclosed
US-20250034127-A1 AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR DISEASES OF THE CNS UNIVERSITÉ PARIS CITÉ (FR) 2025-01-30 US disclosed
EP-4433162-A1 AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR DISEASES OF THE CNS Samsara Therapeutics Inc. (US) 2024-09-25 EP disclosed
CN-118647613-A Autophagy inducing compounds and uses thereof, in particular for central nervous system diseases 轮回治疗公司 2024-09-13 CN disclosed
CN-118308790-A Adjustable double A-site hybrid ferroelectric perovskite single crystal photovoltaic device and preparation method and application thereof 暨南大学 2024-07-09 CN disclosed
WO-2024020084-A1 HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 BRISTOL-MYERS SQUIBB COMPANY (US) 2024-01-25 WO disclosed
EP-3640248-B1 AMINOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF BEIJING ADAMADLE BIOTECHNOLOGY LLC (CN) 2023-08-23 EP disclosed
CN-1665807-A Novel physiolgically active substances MERCIAN CORP (JP) 2005-09-07 CN disclosed
EP-1548121-A1 NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES MERCIAN CORPORATION (JP) 2005-06-29 EP disclosed
EP-1541570-A1 NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCE MERCIAN CORPORATION (JP) 2005-06-15 EP disclosed
EP-1508570-A1 NOVEL PHYSIOLGICALLY ACTIVE SUBSTANCES MERCIAN CORPORATION (JP) 2005-02-23 EP disclosed
CN-1143848-C 2-arylethyl- (piperidin-4-ylmethyl) amine derivatives as muscarinic receptor antagonists - 2004-03-31 CN disclosed
WO-2003044014-A1 INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-05-30 WO disclosed
CN-1295563-A 2-arylethyl- (piperidin-4-ylmethyl) amine derivatives as muscarinic receptor antagonists HOFFMANN LA ROCHE (CH) 2001-05-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250034127-A1 AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR DISEASES OF THE CNS SQSTM1, TFEB, BECN1 SMN1; SMN2 706/4885KDM4E 2987/4885EPHX1 2268/4885
US-20080214815-A1 Process for preparing phenoxypyridine derivatives FIP1L1, SKP1, TET2 SMN1; SMN2 2408/4885KDM4E 331/4885EPHX1 3360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.